211At-TLX-102

N/A

Report date: 2025/11/21 17:15:34
NME

Base Information

Drug Name211At-TLX-102
Drug Alias Name211At-TLX-102
ClassificationRadiation-emitting products > Nuclides > Astatine > 211AtRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionRadionuclide imaging enhancersL-type amino acid transporter 1 inhibitors
TargetsL-type amino acid transporter 1
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTelix Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTelix Pharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A